Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials
Share
Why It Matters
Retention Pharmaceuticals raised $45 million by selling new company shares. They will use this money to test a new blood pressure medicine.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.